CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.
- DOI
- 10.1136/jitc-2021-002446
- Published
- 2021-07-01
- Container
- J Immunother Cancer
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- supportingDirectory of Open Access Journals: A matching record was returned by DOAJ.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1136/jitc-2021-002446,
title = {CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.},
author = {Sanborn RE and Hamid O and de Vries EG and Ott PA and Garcia-Corbacho J and Boni V and Bendell J and Autio KA and Cho DC and Plummer R and Stroh M and Lu L and Thistlethwaite F.},
year = {2021},
journal = {J Immunother Cancer},
doi = {10.1136/jitc-2021-002446},
url = {https://doi.org/10.1136/jitc-2021-002446}
}RIS
TY - JOUR TI - CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study. AU - Sanborn RE AU - Hamid O AU - de Vries EG AU - Ott PA AU - Garcia-Corbacho J AU - Boni V AU - Bendell J AU - Autio KA AU - Cho DC AU - Plummer R AU - Stroh M AU - Lu L AU - Thistlethwaite F. PY - 2021 JO - J Immunother Cancer DO - 10.1136/jitc-2021-002446 UR - https://doi.org/10.1136/jitc-2021-002446 ER -
APA
RE, S., O, H., EG, D. V., PA, O., J, G., V, B., J, B., KA, A., DC, C., R, P., M, S., L, L., & F., T. (2021). CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study.. J Immunother Cancer. https://doi.org/10.1136/jitc-2021-002446
Source records
- europe-pmc · retrieved 2026-09-25T10:48:34.311Z
- doaj · retrieved 2026-09-25T10:48:34.304Z